The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...
That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...
Zacks Investment Research on MSN
GSK to boost respiratory & immunology pipeline with $2.2B RAPT buyout
GSK plc GSK announced that it has entered into a definitive agreement to acquire California-based biotech RAPT Therapeutics ...
RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.
GSK entered into a definitive agreement to acquire RAPT Therapeutics, including RAPT’s long-acting anti-immunoglobulin E (IgE ...
The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines businesses.
It is estimated that around 10% of the US population has peanut allergies, a medical emergency that can be treated but not cured. Compared to those without allergies, these individuals are at a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback